The authors investigated the prognostic impact of pretransplantation molecular measurable residual disease in adult patients with acute myeloid leukemia who had lysine methyltransferase 2a rearrangem…
CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.
Speakers at the 2024 American Urological Association (AUA) annual meeting highlighted the innovations and advancements that are pushing the field of urology forward.
An abstract is unavailable.
China’s NMPA has approved taletrectinib for locally advanced or metastatic ROS1-positive non–small cell lung cancer after a previous ROS1 TKI.
Zongertinib demonstrated clinically meaningful efficacy in previously treated HER2-mutated non–small cell lung cancer.
ASTRO welcomes nominations for participation in upcoming practice guidelines. Please complete this form for consideration.
Phase 1 data may support further development of ZN-1041 combination therapies for a larger breast cancer population.
